Biosimilars Market Size, Share, Trends, Competitive Strategies, Analysis, Key Players & Forecast by 2030 - PowerPoint PPT Presentation

About This Presentation
Title:

Biosimilars Market Size, Share, Trends, Competitive Strategies, Analysis, Key Players & Forecast by 2030

Description:

According to the report, the global Biosimilars market was estimated to be over US$ 4,500 Mn in 2018. It is anticipated to grow at a double digit CAGR from 2019 to 2030. – PowerPoint PPT presentation

Number of Views:83

less

Transcript and Presenter's Notes

Title: Biosimilars Market Size, Share, Trends, Competitive Strategies, Analysis, Key Players & Forecast by 2030


1
Market Industry Reports
Biosimilars Market Growth, Size, Share and Top
Trends 2019-2030
2
Biosimilars Market by Product (Recombinant
Glycosylated Proteins (Monoclonal Antibodies
(Rituximab, Adalimumab, and Infliximab),
Erythropoietin, and Follitropin), Recombinant
Non-Glycosylated Proteins (Insulin, Granulocyte
Colony Stimulating Factor, Recombinant Human
Growth Hormone and Interferon (Interferon-Alpha
and Interferon-Beta)), Recombinant Peptides
(Glucagon and Calcitonin)), Type of Manufacturing
(In-house Manufacturing, and Contract
Manufacturing), Disease (Chronic Disease,
Oncology, Autoimmune Disease, Blood disorders,
Infectious Diseases, and Growth Hormone
Deficiency) - Global Analysis Forecast 2019-2030
Biosimilars Market
Market Industry Reports (MIR) has published a new
report titled Biosimilars Market Global Industry
Analysis, Size, Share, Growth, Trends, and
Forecast, 20192030.  According to the report,
the global Biosimilars market was estimated  to
be over US 4,500 Mn in 2018. It is anticipated
to grow at a double digit CAGR from 2019 to
2030. The growth of the biosimilars market can
be attributed to factors such as the increasing
demand for biosimilar drugs due to their
cost-effectiveness and rising incidence of
chronic diseases, which have led to wide-scale
adoption of these products worldwide. To obtain
better insights regarding the market scenario,
prominent players are increasingly focusing on
collaborative initiatives with several institutes
and research centers. For instance, PlantForm
Corporationhas signed an agreement with the
University of Guelph Canada to enhance research
studies in the field of biosimilars and develop
new ones.
3
Biosimilars Market by Product (Recombinant
Glycosylated Proteins (Monoclonal Antibodies
(Rituximab, Adalimumab, and Infliximab),
Erythropoietin, and Follitropin), Recombinant
Non-Glycosylated Proteins (Insulin, Granulocyte
Colony Stimulating Factor, Recombinant Human
Growth Hormone and Interferon (Interferon-Alpha
and Interferon-Beta)), Recombinant Peptides
(Glucagon and Calcitonin)), Type of Manufacturing
(In-house Manufacturing, and Contract
Manufacturing), Disease (Chronic Disease,
Oncology, Autoimmune Disease, Blood disorders,
Infectious Diseases, and Growth Hormone
Deficiency) - Global Analysis Forecast 2019-2030
Browse key industry insights spread across
150 pages with market data tables figures
charts from the report, Biosimilars Market by
Product (Recombinant Glycosylated Proteins
(Monoclonal Antibodies (Rituximab, Adalimumab,
and Infliximab), Erythropoietin, and
Follitropin), Recombinant Non-Glycosylated
Proteins (Insulin, Granulocyte Colony Stimulating
Factor, Recombinant Human Growth Hormone and
Interferon (Interferon-Alpha and
Interferon-Beta)), Recombinant Peptides (Glucagon
and Calcitonin)), Type of Manufacturing (In-house
Manufacturing, and Contract Manufacturing),
Disease (Chronic Disease, Oncology, Autoimmune
Disease, Blood disorders, Infectious Diseases,
and Growth Hormone Deficiency) - Global Analysis
Forecast 2019-2030. in detail along with the
table of contentshttps//www.marketindustryreport
s.com/67/biosimilars-market Major Players in the
Biosimilars Market The prominent players in the
global biosimilars market are Pfizer, Sandoz
International, Teva Pharmaceuticals, Amgen,
Biocon, Dr. Reddys Laboratories, Celltrion,
Samsung Biologics, Stada Arzneimittel AG and
Mylan.
4
Biosimilars Market by Product (Recombinant
Glycosylated Proteins (Monoclonal Antibodies
(Rituximab, Adalimumab, and Infliximab),
Erythropoietin, and Follitropin), Recombinant
Non-Glycosylated Proteins (Insulin, Granulocyte
Colony Stimulating Factor, Recombinant Human
Growth Hormone and Interferon (Interferon-Alpha
and Interferon-Beta)), Recombinant Peptides
(Glucagon and Calcitonin)), Type of Manufacturing
(In-house Manufacturing, and Contract
Manufacturing), Disease (Chronic Disease,
Oncology, Autoimmune Disease, Blood disorders,
Infectious Diseases, and Growth Hormone
Deficiency) - Global Analysis Forecast 2019-2030
Rise in Demand of Biosimilars Due to
Costeffectiveness Over the years, the rise in
demand of biosimilars has played a vital role in
contributing to the growth of the global
biosimilars industry. The high demand for
biosimilars is attributed to their greater
effectiveness and lower cost than other
alternatives. Several countries, including
Europe, North America, India, and other
developing countries, have emerged as essential
contributors to global biosimilars industry.
While generic drugs have a profit margin
potential of 20, the biosimilars products is
anticipated to gain a potential profit margin of
30. Moreover, cost of treatment by innovator
drug is much higher than that by biosimilars,
which has also contributed effectively to the
growing demand of these products. Download free
PDF sample Copy_at_https//www.marketindustryreports.
com/pdf/67 Biosimilars Market in Asia Pacific
to Grow at Rapid Rate Asia Pacific is estimated
to witness the highest CAGR in the market during
the forecast period. Patent expiry of biologic
products, the launch of new biosimilars, rising
incidence of chronic disorders, and the emergence
of new market players are anticipated to present
lucrative growth opportunities to the global
biosimilars market in this region. Furthermore,
supportive government healthcare regulations and
norms are expected to present an attractive
growth prospect for the market in the coming
years.
5
Biosimilars Market by Product (Recombinant
Glycosylated Proteins (Monoclonal Antibodies
(Rituximab, Adalimumab, and Infliximab),
Erythropoietin, and Follitropin), Recombinant
Non-Glycosylated Proteins (Insulin, Granulocyte
Colony Stimulating Factor, Recombinant Human
Growth Hormone and Interferon (Interferon-Alpha
and Interferon-Beta)), Recombinant Peptides
(Glucagon and Calcitonin)), Type of Manufacturing
(In-house Manufacturing, and Contract
Manufacturing), Disease (Chronic Disease,
Oncology, Autoimmune Disease, Blood disorders,
Infectious Diseases, and Growth Hormone
Deficiency) - Global Analysis Forecast 2019-2030
2 RESEARCH METHODOLOGY 2.1 Research
Framework 2.2 Data Collection Technique 2.3
Data Sources 2.3.1 Secondary
Sources 2.3.2 Primary Sources 2.4
Market Estimation Methodology 2.4.1 Bottoms
Up Approach 2.4.2 Top Down Approach
Table of content
1 INTRODUCTION 1.1 Research
Methodology 1.2 Market Definition 1.3
Market Ecosystem 1.3.1 Market
Classification 1.3.2 Geographic Scope 1.3.3
Years Considered for the Study 1.3.3.1
Historical Years 2016 2017
Visit https//www.marketindustryreports.com/67/b
iosimilars-market
6
CONTACT US
502, Sai Radhe, Kennedy Road, Behind Hotel
Sheraton Grand, Near Pune Station, Pune 411
001,Maharashtra, India Email sales_at_marketindustr
yreports.com Phone 91 8956 767 535
Connect with us
Visit
https//www.marketindustryreports.com/contact-us
7
About Market Industry Reports
Market Industry Reports is a global leader in
market measurement advisory services, Market
Industry Reports is at the forefront of
innovation to address the worldwide industry
trends and opportunities. We identified the
caliber of market dynamics hence we excel in
the areas of innovation and optimization,
integrity, curiosity, customer and brand
experience, and strategic business intelligence
through our research. We offer our clients a
unique depth of market intelligence in an
actionable format to move their business forward.
Our analysis incorporates the consumer study in
more than 100 countries that provide a tactical
approach to drive the sustained growth for the
business. We continue to pioneer state-of-the-art
approach in research analysis that makes
complex world simpler to stay ahead of the curve.
By nurturing the perception of genius and
optimized market intelligence we bring proficient
contingency to our clients in the evolving world
of technologies, megatrends and industry
convergence.
Visit https//www.marketindustryreports.com/67/b
iosimilars-market
Write a Comment
User Comments (0)
About PowerShow.com